Investors
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue.
We are a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living.
We operate in more than 100 countries worldwide. We are a constituent of the UK’s FTSE100 and our shares are traded in London and New York. We have a progressive dividend policy and have paid a dividend to shareholders every year since 1937.
We develop and produce pioneering products across our three business units: Advanced Wound Management, Sports Medicine & ENT and Orthopaedics.
In December 2021 we announced our Strategy for Growth. Through this we will compound our outperformance in Advanced Wound Management and Sports Medicine & ENT, and regain momentum in Orthopaedics. Our ambition is to transform to a structurally higher growth company.
Our Strategy for Growth is based on three pillars.
The Strategy for Growth will be delivered through the key value builders of productivity, commercial execution, innovation and acquisitions
The 12-point plan supports the first two pillars of the Strategy for Growth and will improve business performance by maximising the opportunities we have built, and addressing the challenges. Through the 12-point plan we are fundamentally changing the way we operate and deliver results.
The 12-point plan is focused on:
Smith+Nephew competes in global markets worth around $43 billion, which are driven by long term trends and were growing at approximately 4% annually prior to 2020 and the impact of COVID.
We released our second quarter 2024 results on Thursday 1 August 2024.
Webcast
Watch the recording of our live webcast, presented by Deepak Nath, Chief Executive Officer and John Rogers, Chief Financial Officer.
The Annual General Meeting (AGM) was held at 12pm on Wednesday 1 May 2024 at Smith+Nephew Academy London, Building 5, Croxley Park, Hatters Lane, Watford, WD18 8YE.
1. Invest
2. Acquire
3. Maintain
4. Return
A number of leading sellside analysts cover our company and regularly write about us.
Analyst | Company | City |
Virendra Chauhan | AlphaValue | Paris |
Julien Ouaddour | Bank of America | London |
Hassan Al-Wakeel | Barclays | London |
Sam England | Berenberg Bank | London |
Lisa Bedell Clive | Bernstein | London |
Caitlin Cronin | Canaccord Genuity | New York |
Veronika Dubajova | Citi | London |
Richard Felton | Goldman Sachs | London |
Sezgi Oezener | HSBC | Dusseldorf |
Julien Dormois | Jefferies | Paris |
David Adlington | J P Morgan Cazenove | London |
Seb Jantet | Liberum | London |
Robert Davies | Morgan Stanley | London |
Oliver Metzger | ODDO BHF | Frankfurt |
Jack Reynolds-Clark | RBC | London |
Ed Ridley-Day | Redburn | London |
Dylan Van Haaften | Stifel | London |
Graham Doyle | UBS | London |
Smith+Nephew has solicited credit ratings from Moody’s and S&P, which are assigned as:
Moody's | S&P | |
Long-term rating | Baa2 | BBB+ |
Outlook | Stable | Stable |